Senescence-accelerated mouse (SAM): A biogerontological resource in aging research

Neurobiology of Aging

Volumn 20, Issue 2, 1999, Pages 105-110

  Takeda, Toshio ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

Accelerated senescence; Aging; Animal model; Pathobiological phenotypes; SAM

Indexed keywords

AFFECTIVE NEUROSIS; ARTICLE; BRAIN ATROPHY; CIRCADIAN RHYTHM; HEARING IMPAIRMENT; LEARNING DISORDER; LIFESPAN; MEMORY; MOUSE; NEUROBIOLOGY; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SENESCENCE;

AGING; AMYLOIDOSIS; ANIMALS; DISEASE MODELS, ANIMAL; GERIATRICS; JOINT DISEASES; MICE; MICE, INBRED STRAINS; OSTEOPOROSIS; PHENOTYPE;

EID: 0032847560     PISSN: 01974580     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0197-4580(99)00008-1     Document Type: Article

References (55)

1. Butterfield DA, Howard BJ, Yatin S, Allen KL, Carney JM. Free radical oxidation of brain proteins in accelerated senescence and its modulation by N-tert-butyl-α-phenylnitrone. Proc Natl Acad Sci USA 1997;94:674-8.
2. Chen WH, Hosokawa M, Tsuboyama T, Ono T, Iizuka T, Takeda T. Age-related changes in the temporomandibular joint of the senescence accelerated mouse (SAM) SAM-P/3 as a new murie model of degenerative joint disease. Am J Pathol 1989;135:379-85.
3. Chen WH, Hosokawa M, Wang J, Iizuka T, Takeda T. Senescenceaccelerated mouse, SAMP3, as a murine model of degenerative joint disease. In: Takeda T, editor. The SAM model of senescence. Amsterdam: Excerpta Medica, 1994. p. 227-30.
4. Cotran RS, Kumar V, Robbins SL. Diseases of aging. In: Robbins pathologic basis of disease. Philadelphia: W.B. Saunders, 1989. p. 543-51.
5. Edamatsu R, Mori A, Packer L. The spin-trap N-tert-αphenyl-butylnitrone prolongs the life span of the senescence accelerated mouse. Biochem Biophys Res Commun 1995;211:847-9.
6. Fujibayashi Y, Waki A, Yonekura Y, Yokoyama A. In vivo visualization of abnormal brain aging by PET and SPECT. In: Ishii Y, Yonekura Y, Fujibayashi Y, Sadato N, editors. Recent advances in biomedical imaging. Amsterdam: Elsevier, 1997. p. 171-7.
7. Fujisawa H, Nishikawa T, Zhu B-H, et al. Accelerated aging of dermal fibroblast-like cells from the senescence-accelerated mouse (SAM): acceleration of changes in DNA ploidy associated with in vitro cellular aging. J Gerontol 1998;53A:B11-B17.
8. Higuchi K, Matsumura A, Honma A, et al. Systemic senile amyloid in senescence-accelerated mice: a unique fibril protein demonstrated in tissues from various organs by the unlabeled immunoperoxidase method. Lab Invest 1983;48:231- 40.
9. Higuchi K, Yonezu T, Kogishi K, et al. Purification and characterization of a senile amyloid-related antigenic substance (apoSAS-SAM) from mouse serum. J Biol Chem 1986;261:12834-40.
10. Higuchi K, Naiki H, Kitagawa K, Hosokawa M, Takeda T. Mouse senile amyloidosis ASSAM amyloidosis in mice presents universally as a systemic age-associated amyloidosis. Virchows Arch B Cell Pathol 1991;60:231-9.
11. Higuchi K, Kitagawa K, Naiki H, Hanada K, Hosokawa M, Takeda T. Polymorphism of apolipoprotein A-II (apoA-II) among inbred strains of mice. Relationship between the molecular type of apoA-II and mouse senile amyloidosis. Biochem J 1991;279:427-33.
12. Hosokawa M, Kasai R, Higuchi K, et al. Grading score system: a method for evaluation of the degree of senescence in senescence accelerated mouse (SAM). Mech Ageing Dev 1984;26:91-102.
13. Hosokawa M, Ashida Y, Nishikawa T, Takeda T. Accelerated aging of dermal fibroblast-like cells from senescence-accelerated mouse (SAM). 1. Acceleration of population aging in vitro. Mech Ageing Dev 1994;74:65-77.
14. Jilka RL, Weinstein RS, Takahashi K, Parfitt AM, Manolagas SC. Linkage of decreased bone mass with impaired osteoblastogenesis in a murine model of accelerated senescence. J Clin Invest 1996;97:1732-40.
15. Kajkenova O, Lecka-Czernik B, Gubrij I, et al. Increased adipogenesis and myelopoiesis in the bone marrow of SAMP6, a murine model of defective osteoblastogenesis and low turnover osteopenia. J Bone Miner Res 1997;12:1772-9.
16. Kishikawa M, Sakae M. Herbal medicine and the study on ageing in senescence accelerated mice (SAMP1TA/Ngs). Exp Gerontol 1997;33:229-42.
17. Kitado H, Higuchi K, Takeda T. Molecular genetic characterization of the senescence-accelerated mouse (SAM) strains. J Gerontol 1994;49:B247-B254.
18. Kitamura Y, Ohnuki T, Nomura Y. Effects of bifemelane hydrochloride, a brain function improver, on muscarinic receptors in the CNS of senescence-accelerated mouse. Jpn J Pharmacol 1991;56:231-5.
19. Kohno A, Yonezu T, Matsushita M, et al. Chronic food restriction modulates the advance of senescence in the senescence accelerated mouse (SAM). J Nutr 1985;115:1259-66.
20. Komura S, Yoshino K, Kondo K, Yagi K. Lipid peroxide levels in the skin of the senescence-accelerated mouse. J Clin Biochem Nutr 1988;5:255- 60.
21. Kunisada T, Higuchi K, Aota S, Takeda T, Yamagishi H. Molecular cloning and nucleotide sequence of cDNA for murine senile amyloid protein: nucleotide substitutions found in apolipoprotein A-II cDNA of senescence accelerated mouse (SAM). Nucleic Acids Res 1986;14:5729-40.
22. Lee DW, Sohn HO, Lim HB, Lee YG, Chung MH. Comparison of sister chromatid exchange rates in bone marrow cells of SAMR1 and SAMP1 with age and effect of Korean ginseng extract on sister chromatid exchange rate. In: Takeda T, editor. The SAM model of senescence. Amsterdam: Excerpta Medica, 1994. p. 129-31.
23. Masoro EJ. Animal models in aging research. In: Schnneider EL, Rowe JW, editors. Handbook of the biology of aging, 3rd Edition. San Diego: Academic Press, 1990. p. 72-94.
24. Matsumura A, Higuchi K, Shimizu K, et al. A novel amyloid fibril protein isolated from senescence-accelerated mice. Lab Invest 1982;47:270 -5.
25. Matsushita M, Tsuboyama T, Kasai R, et al. Age-related changes in bone mass in the senescence-accelerated mouse (SAM) SAM-R/3 and SAM-P/6 as new murine models for senile osteoporosis. Am J Pathol 1986;215:276-83.
26. Meguro K, Yanai K, Sakai N, et al. Effects of thioperamide, a histamine H antagonist, on the step-through passive avoidance response and histidine decarboxylase activity in senescence-accelerated mice. Pharmacol Biochem Behav 1995;50:321-5.
27. Miyamoto M, Hirai K, Heya T, Nagaoka A. Effects of sustained release formulation of thyrotropin-releasing hormone on behavioral abnormalities in senescence-accelerated mice. Eur J Pharmacol 1994;271:357- 66.
28. Naiki H, Higuchi K, Hosokawa M, Takeda T. Fluorometric determination of amyloid fibrils in vitro using the fluorescent dye, thioflavine T. Anal Biochem 1989;177:244 -9.
29. Naiki H, Higuchi K, Nakakuki K, Takeda T. Kinetic analysis of amyloid fibril polymerization in vitro. Lab Invest 1991;65:104 -10.
30. Naiki H, Higuchi K, Shimada A, Takeda T, Nakakuki K. Genetic analysis of murine senile amyloidosis. Lab Invest 1993;68:332-7.
31. Nisitani S, Hosokawa M, Sasaki MS, et al. Acceleration of chromosome aberrations in senescence-accelerated strains of mice. Mutat Res 1990;237:221- 8.
32. Odagiri Y, Uchida H, Hosokawa M, Takemoto K, Morley AA, Takeda T. Accelerated accumulation of somatic mutations with age in lymphocytes of the senescence-accelerated mouse (SAM). Nature Genet (Correspondence) 1998;19:116 -7.
33. Oomura Y, Sasaki K, Li A, et al. Acidic fibroblast growth factor protects memory and immunoreactivity impairment in senescence accelerated mice. Neurobiology 1995;3:371- 80.
34. Park JW, Choi CH, Kim MS, Chung MH. Oxidative status in senescence-accelerated mice. J Gerontol 1996;51A:B337-B345.
35. Pearce L, Brown WH. Hereditary premature senescence of the rabbit. I. Chronic form: genetic features. J Exp Med 1960;111:485-504.
36. Pearce L, Brown WH. Hereditary premature senescence of the rabbit. II. Acute form: genetic features. J Exp Med 1960;111:505-16.
37. Popp DW. Use of congenic mice to study the genetic basis of degenerative disease. Birth Defects 1978;14:261-79.
38. Riggs BL, Melton LJ. Evidence for two distinct syndromes of involutional osteoporosis. Am J Med 1983;75:899 -901.
39. Sprott RL, Austad SN. Animal models for aging research. In: Schneider EL, Rowe JW, editors. Handbook of the biology of aging, 4th Edition. San Diego: Academic Press, 1995. p. 3-23.
40. Suda T, Miyama K, Uchiyama Y, Katagiri T, Yamaguchi A, Sato T. Osteoporotic bone changes in SAMP6 are due to a decrease in osteoblast progenitor cells. In: Takeda T, editor. The SAM model of senescence. Amsterdam: Excerpta Medica, 1994. p. 47-52.
41. Takahashi K, Tsuboyama T, Matsushita M, et al. Effective intervention of low peak bone mass and bone modeling in the spontaneous murine model of senile osteoporosis, SAM-P/6, by Ca supplement and hormone treatment. Bone 1994;15:209 -15.
42. Takeda T, Hosokawa M, Takeshita S, et al. A new murine model of accelerated senescence. Mech Ageing Dev 1981;17:183-94.
43. Takeda T, Hosokawa M, Higuchi K. Senescence-accelerated mouse (SAM): a novel murine model of accelerated senescence. J Am Geriatr Soc 1991;39:911-9.
44. Takeda T, Hosokawa M, Higuchi K. Senescence-accelerated mouse (SAM): a novel murine model of aging. In: Takeda T, editor. The SAM model of senescence. Amsterdam: Excerpta Medica, 1994. p. 15-22.
45. Takeda T, Shimizu K, Chen WH. Amyloid arthropathy and degenerative joint disease in the senescence-accelerated mouse (SAM). In: Mohr U, Dungworth DL, Capen CC, Carlton WW, Sundberg JP, Ward JM, editors. Pathobiology of the aging mouse, Vol. 2. Washington, D.C.: ILSI Press, 1996. p. 455-71.
46. Takeda T, Matsushita T, Kurozumi M, Takemura K, Higuchi K, Hosokawa M. Pathobiology of the senescence-accelerated mouse (SAM). Exp Gerontol 1997;32:117-27.
47. Takeda T, Higuchi K, Hosokawa M. Senescence-accelerated mouse (SAM): with special reference to development and pathobiological phenotypes. ILAR J 1997;38:109 -18.
48. Takeshita S, Hosokawa M, Irino M, et al. Spontaneous age-associated amyloidosis in senescence-accelerated mouse (SAM). Mech Ageing Dev 1982;20:13-23.
49. Tsuboyama T, Takahashi K, Matsushita M, et al. Decreased endosteal formation during cortical bone modelling in SAMP-P/6 mice with a low peak bone mass. Bone Miner 1989;7:1-12.
50. Umezawa M, Hanada K, Naiki H, et al. Effects of dietary restriction on age-related immune dysfunction in the senescence accelerated mouse (SAM). J Nutr 1990;120:1393-1400.
51. Umezawa M, Ohta A, Tojo H, Yagi H, Hosokawa M, Takeda T. Dietary α-linolenate/linoleate balance influences learning and memory in the senescence-accelerated mouse (SAM). Brain Res 1995;669:225-33.
52. Weindruch R. Animal models. In: Masoro EJ, editor. Handbook of physiology. Section 11: aging. New York, Oxford University Press, 1995. p. 37-52.
53. Yonezu T, Higuchi K, Tsunasawa S, Takagi S, Sakiyama F, Takeda T. High homology is present in the primary structures between murine senile amyloid protein (ASSAM) and human apolipoprotein A-II. FEBS Lett 1986;203:149 -52.
54. Yonezu T, Tsunasawa S, Higuchi K, et al. A molecular-pathologic approach to murine senile amyloidosis: serum precursor-apolipoprotein A-II variant (pro5-gln) presents only in senile amyloidosis-prone SAM-P/1 and SAM-P/2 mice. Lab Invest 1987;57:65-70.
55. Zhao XH, Awaya A, Kobayashi H, Ohnuki T, Tokumitsu Y, Nomura Y. Effects of repeated administrations of facteur thymique serique (FTS) on biochemical changes related to aging in senescence-accelerated mouse (SAM). Jpn J Pharmacol 1990;53:311-9.